Skip to content

Puma ‘attractive M&A target’: Citi

July 3, 2017

Citi maintains Buy on Puma Biotechnology (NASDAQ: PBYI) price target of $105.00.

Analyst Dr. Yigal Nochomovitz says the company looks to be an attractive M&A target and notes that when sales/marketing is stripped away and a 8% WACC (pharma WACC) is used the stock is worth $136 per share.

http://bit.ly/2sYXLmv

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: